| Literature DB >> 31816866 |
Olympia Kouzi1, Eleni Pontiki1, Dimitra Hadjipavlou-Litina1.
Abstract
Indandiones are a relatively new group of compounds presenting a wide range of biological activities. The synthesis of these compounds was performed via a Knoevenagel reaction between an aldehyde and 1,3-indandione and were obtained with a yield up to 54%. IR, 1H-Nucleic Magnetic Resonance (NMR), 13C-NMR, LC/MS ESI+ and elemental analysis were used for the confirmation of the structures of the novel derivatives. Lipophilicity values of compounds were calculated theoretically and experimentally by reversed chromatography method as values RM. The novel derivatives were studied through in vitro and in vivo experiments for their activity as anti-inflammatory and antioxidant agents and as inhibitors of lipoxygenase, trypsin, and thrombin. The inhibition of the carrageenin-induced paw edema (CPE) was also determined for representative structures. In the above series of experiments, we find that all the compounds showed moderate to satisfying interaction with the stable DPPH free radical in relation to the concentration and the time 2-arylidene-1-indandione (10) was the strongest. We observed moderate or very low antioxidant activities for selected compounds in the decolorization assay with ABTS+•. Most of the compounds showed high anti-lipid peroxidation of linoleic acid induced by AAPH.2-arylidene-1-indandione (7) showed a strongly inhibited soybean LOX. Only 2-arylidene-1-indandione (3) showed moderate scavenging activity of superoxide anion, whereas 2-arylidene-1-indandione (8) and 2-arylidene-1-indandione (9) showed very strong inhibition on proteolysis. 2-arylidene-1-indandione (8) highly inhibited serine protease thrombin. 2-arylidene-1-indandiones (7, 8 and 9) can be used as lead multifunctional molecules. The compounds were active for the inhibition of the CPE (30-57%) with 2-arylidene-1-indandione (1) being the most potent (57%). According to the predicted results a great number of the derivatives can cross the Blood-Brain Barrier (BBB), act in CNS and easily transported, diffused, and absorbed. Efforts are conducted a) to correlate quantitatively the in vitro/in vivo results with the most important physicochemical properties of the structural components of the molecules and b) to clarify the correlation of actions among them to propose a possible mechanism of action. Hydration energy as EHYDR and highest occupied molecular orbital (HOMO) better describe their antioxidant profile whereas the lipophilicity as RM values governs the in vivo anti-inflammatory activity. Docking studies are performed and showed that soybean LOX oxidation was prevented by blocking into the hydrophobic domain the substrates to the active site.Entities:
Keywords: 2-arylidene-1,3-indandiones; Lipinski “Rule of five”; antioxidants; lipoxygenase inhibitors
Mesh:
Substances:
Year: 2019 PMID: 31816866 PMCID: PMC6930570 DOI: 10.3390/molecules24234411
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1General synthesis of the new derivatives: 0.0068 mol of 1,3-indandione, 0.0075 mol of the corresponding arylaldehyde in 30 mL of absolute ethanol and piperidine 0.06 mL. Yields of the products are given in parentheses.
Molecular properties prediction-Lipinski “Rule of five”. Drug-likeness of the synthesized compounds.
| Compd. | milog | TPSA b | No Atoms | No O,N c | No OH, NH d | No Violations | No Rotational Bonds e | Volume f | MW g | logBBB h |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 2.79 | 34.14 | 17 | 2 | 0 | 0 | 1 | 200.71 | 240.28 | 0.255 |
|
| 3.16 | 34.14 | 18 | 2 | 0 | 0 | 1 | 217.27 | 254.31 | 0.312 |
|
| 2.52 | 47.28 | 18 | 3 | 0 | 0 | 1 | 208.12 | 238.24 | 0.082 |
|
| 2.89 | 34.14 | 18 | 2 | 0 | 0 | 1 | 209.99 | 234.25 | 0.270 |
|
| 3.64 | 34.14 | 20 | 2 | 0 | 0 | 2 | 237.41 | 260.29 | 0.387 |
|
| 3.75 | 37.38 | 23 | 3 | 0 | 0 | 3 | 283.32 | 303.36 | 0.371 |
|
| 4.62 | 43.38 | 25 | 3 | 0 | 0 | 3 | 290.39 | 326.35 | 0.446 |
|
| 5.35 | 43.38 | 27 | 3 | 0 | 1 | 4 | 325.07 | 419.27 | 0.560 |
|
| 5.94 | 54.37 | 27 | 3 | 3 | 1 | 3 | 350.38 | 362.47 | 0.541 |
|
| 5.94 | 54.37 | 27 | 3 | 1 | 1 | 3 | 350.38 | 362.47 | 0.541 |
|
| 3.09 | 49.93 | 21 | 3 | 1 | 0 | 1 | 238.97 | 273.29 | 0.144 |
|
| 3.04 | 49.93 | 21 | 3 | 1 | 0 | 1 | 238.97 | 273.29 | 0.144 |
N Atoms denotes the number of atoms in the compound; a Logarithm of partition coefficient between-octanol and water (milogP); b Topological polar surface area (TPSA); c Number of hydrogen bond acceptors (n-ON); d Number of hydrogen bond donors (n-OHNH); e Number of rotatable bonds (n-rotb); f Molecular Volume; g Molecular Weight; h blood–brain barrier (logBBB = 0.155 logP − 0.01TPSA + 0.164) [57].
Lipophilicity values: experimental RM%. E Hydration Energy. E(HOMO). Interaction with the stable radical 1,1-diphenyl-picrylhydrazyl (DPPH), In vitro lipoxygenase (LOX) inhibitory activity at 100 µM.
| Compd. | RM a (±SD) b | E | E(HOMO) | RA% 50 µM | RA% 50 µM | RA% 100 µM | RA% 100 µM | RA% 200 µM | RA% 200 µM | LOX |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 0.031 ± 0 | −20.48 | −0.310777 | 2 | 0 | 16 | 16 | 2 | 6 | 32.6 |
|
| 0.031 ± 0 | −17.37 | −0.309938 | 2 | 2 | 16 | 16 | 4 | 7 | 45 |
|
| 0.014 ± 0 | −7.67 | 0.291110 | 20 | 23 | 37 | 40 | 61 | 75 | 35.7 |
|
| −0.615 ± 0.02 | −6.53 | −0.306356 | 5 | 10 | 26 | 32 | 23 | 32 | 35 |
|
| 0.158 ± 0 | −6.71 | −0.302600 | 21 | 25 | 44 | 48 | 57 | 72 | 26.4 |
|
| −0.527 ± 0 | −9.86 | −0.271983 | 6 | 6 | 22 | 23 | 15 | 18 | 17.7 |
|
| −0.196 ± 0.02 | −7.30 | −0.303773 | 27 | 35 | 40 | 50 | 75 | 85 | 67.3 |
|
| * | −9.31 | −0.314300 | 4 | 5 | 7 | 7 | 0 | 0 | 3.6 |
|
| −1.038 ± 0 | −5.68 | −0.306356 | 4 | 3 | 3 | 1 | 6 | 6 | no |
|
| −0.103 ± 0 | −5.71 | −0.314300 | 13 | 17 | 100 | 85 | 71 | 71 | no |
|
| −0.196 ± 0.02 | −12.71 | −0.279993 | 2 | 2 | 19 | 19 | 10 | 10 | 38.6 |
|
| −0.134 ± 0.02 | −12.72 | −0.279598 | 3 | 3 | 17 | 17 | 4 | 6 | 58.9 |
|
| - | 81 | 83 | 87 | 93 | 94 | 96 | 93 |
a RM values are the average of at least 5 measurements, b SD standard deviation < 10%; * could not be measured under the reported experimental conditions.
% Anti-lipid peroxidation (AAPH), Decolorization activity ABTS+·% assays. In vitro inhibition of trypsin induced proteolysis (% Trypsin Inh -Iptr%), thrombin inhibition TH%, In vivoanti-inflammatory activity (CPE %).
| Compd. | AAPH% 100 µΜ | ABTS +. % 100 µΜ | Iptr% 100 µΜ | TH% 100 µΜ | CPE a % |
|---|---|---|---|---|---|
|
| 90 | 9 | no | no | 57 ** |
|
| 92 | 2 | no | - | 45 * |
|
| no | 20 | 17 | 39 | 50 * |
|
| no | 19 | 4 | no | 28 * |
|
| no | no | no | - | - |
|
| 9 | 22 | 29 | 19 | - |
|
| 82 | 37 | 33 | no | 41 ** |
|
| 79 | 16 | 85 | 100 | 46 * |
|
| 96 | no | 98 | 0 | - |
|
| 85 | 39 | no | 27 | 42 * |
|
| no | 8 | 6 | - | - |
|
| 31 | no | no | - | 42 ** |
|
| 93 | 91 | |||
|
| 47 | ||||
|
| 54 | ||||
|
| 98 |
* p < 0.01, ** p < 0.05. a % of reduction of the rat paw edema (CPE %) induced by carrageenin at the dose of 0.01 mmol/Kg/body weight.no: no action under the experimental conditions.
Figure 1Preferred docking pose of 7(depicted in blue) bound to soybean lipoxygenase (LOX-1).
Comparison table with multi-target pleiotropic compounds.
| Compd. | % LOX Inh. 100 μM | % IPr 100 μΜ | % TH 100 μΜ | AAPH% 100 μM | % CPE |
|---|---|---|---|---|---|
|
| 67.3 | 82 | 41 | ||
|
| 85 | 100 | 79 | 46 | |
|
| 98 | 96 |